308 related articles for article (PubMed ID: 29633951)
1. [Radiotherapy for local disease in metastatic prostate cancer.].
Cambeiro M; Calvo FA
Arch Esp Urol; 2018 Mar; 71(3):298-305. PubMed ID: 29633951
[TBL] [Abstract][Full Text] [Related]
2. What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?
Baboudjian M; Roubaud G; Fromont G; Gauthé M; Beauval JB; Barret E; Brureau L; Créhange G; Dariane C; Fiard G; Mathieu R; Ruffion A; Rouprêt M; Renard-Penna R; Sargos P; Ploussard G;
World J Urol; 2023 Aug; 41(8):2033-2041. PubMed ID: 36484817
[TBL] [Abstract][Full Text] [Related]
3. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
4. Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer.
Niazi T; Elakshar S; Stroian G
Curr Opin Support Palliat Care; 2018 Sep; 12(3):351-358. PubMed ID: 29979320
[TBL] [Abstract][Full Text] [Related]
5. [(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results.
Pasqualetti F; Panichi M; Sainato A; Matteucci F; Galli L; Cocuzza P; Ferrazza P; Coraggio G; Pasqualetti G; Derosa L; Sollini M; Mannelli L; Ortori S; Monzani F; Ricci S; Greco C; Fabrini MG; Erba PA
Radiat Oncol; 2016 Jan; 11():9. PubMed ID: 26796633
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?
Slaoui A; Albisinni S; Aoun F; Assenmacher G; Al Hajj Obeid W; Diamand R; Regragui S; Touzani A; Bakar A; Mesfioui A; Karmouni T; Ameur A; Elkhader K; Koutani A; Ibnattya A; Roumeguere T; Peltier A
World J Urol; 2019 Nov; 37(11):2343-2353. PubMed ID: 30706122
[TBL] [Abstract][Full Text] [Related]
7. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT
BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647
[TBL] [Abstract][Full Text] [Related]
8. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).
Habl G; Straube C; Schiller K; Duma MN; Oechsner M; Kessel KA; Eiber M; Schwaiger M; Kübler H; Gschwend JE; Combs SE
BMC Cancer; 2017 May; 17(1):361. PubMed ID: 28532400
[TBL] [Abstract][Full Text] [Related]
9. Advances in local and ablative treatment of oligometastasis in prostate cancer.
Yao HH; Hong MKh; Corcoran NM; Siva S; Foroudi F
Asia Pac J Clin Oncol; 2014 Dec; 10(4):308-21. PubMed ID: 25155557
[TBL] [Abstract][Full Text] [Related]
10. Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO).
D'Angelillo RM; Francolini G; Ingrosso G; Ravo V; Triggiani L; Magli A; Mazzeo E; Arcangeli S; Alongi F; Jereczek-Fossa BA; Pergolizzi S; Pappagallo GL; Magrini SM
Crit Rev Oncol Hematol; 2019 Jun; 138():24-28. PubMed ID: 31092381
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
Phillips R; Shi WY; Deek M; Radwan N; Lim SJ; Antonarakis ES; Rowe SP; Ross AE; Gorin MA; Deville C; Greco SC; Wang H; Denmeade SR; Paller CJ; Dipasquale S; DeWeese TL; Song DY; Wang H; Carducci MA; Pienta KJ; Pomper MG; Dicker AP; Eisenberger MA; Alizadeh AA; Diehn M; Tran PT
JAMA Oncol; 2020 May; 6(5):650-659. PubMed ID: 32215577
[TBL] [Abstract][Full Text] [Related]
12. A Review of Stereotactic Body Radiation Therapy in the Management of Oligometastatic Prostate Cancer.
Zhang B; Leech M
Anticancer Res; 2020 May; 40(5):2419-2428. PubMed ID: 32366385
[TBL] [Abstract][Full Text] [Related]
13. Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials.
Connor MJ; Smith A; Miah S; Shah TT; Winkler M; Khoo V; Ahmed HU
Eur Urol Oncol; 2020 Oct; 3(5):582-593. PubMed ID: 32891600
[TBL] [Abstract][Full Text] [Related]
14. The cytoreductive radical prostatectomy in metastatic prostate cancer.
Vladimír Š; Zuzana S; Hana Š
Klin Onkol; 2022; 35(1):55-62. PubMed ID: 35236082
[TBL] [Abstract][Full Text] [Related]
15. OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer.
Supiot S; Rio E; Pacteau V; Mauboussin MH; Campion L; Pein F
BMC Cancer; 2015 Sep; 15():646. PubMed ID: 26408012
[TBL] [Abstract][Full Text] [Related]
16. [Surgical treatment of local disease in metastatic prostate cancer.].
Gaya JM; Huguet J; Breda A; Palou J
Arch Esp Urol; 2018 Mar; 71(3):288-297. PubMed ID: 29633950
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of primary disease for synchronous metastatic prostate cancer].
Laville A; Coutte A; Blanchard P; Sun R; Deutsch E; Latorzeff I
Cancer Radiother; 2020 Oct; 24(6-7):547-553. PubMed ID: 32855028
[TBL] [Abstract][Full Text] [Related]
18. The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.
Kim J; Park JS; Ham WS
Investig Clin Urol; 2017 Sep; 58(5):307-316. PubMed ID: 28868501
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy of oligometastatic prostate cancer: a systematic review.
Rogowski P; Roach M; Schmidt-Hegemann NS; Trapp C; von Bestenbostel R; Shi R; Buchner A; Stief C; Belka C; Li M
Radiat Oncol; 2021 Mar; 16(1):50. PubMed ID: 33750437
[TBL] [Abstract][Full Text] [Related]
20. Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?
Cahill EM; Pfail JL; Fu MZ; Saraiya B; Mayer T; Stephenson RD; Ennis RD; Hathout L; Deek MP; Ghodoussipour S; Jang TL
Curr Urol Rep; 2023 Jul; 24(7):299-306. PubMed ID: 37017928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
